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 The purpose of this study was to determine the ergogenic response to different 
caffeine doses of 3 mg/kg and 6 mg/kg consumed by trained cyclists 1 hour prior to a 40 
kilometer cycling time trial.  It was hypothesized that there would not be a difference in 
time trial performance following caffeine supplementation of a 3 mg/kg dose as 
compared to a 6 mg/kg dose.  Sixteen male subjects, age 18-40, were initially assessed 
via a VO2max test on an indoor cycle trainer.  Subjects then reported to the lab on 4 
separate occasions following a 10 hour fast and a 24 hour period of abstinence from 
caffeine, for a 40 kilometer time trial on an indoor cycle trainer.  One hour before their 
time trial, subjects were given either 3 mg/kg or 6 mg/kg of caffeine or a placebo in 
capsule form, administered in double-blind fashion along with 22 ounces of a 6% 
carbohydrate/electrolyte solution.   The effects of the different treatments on 40 kilometer 
time trial time, average power output, heart rate, rating of perceived exertion, VO2, and 
respiratory exchange ratio were assessed using Repeated Measures Analysis of Variance 
with treatment as a within-subjects factor.  Caffeine significantly improved 40 kilometer 
time trial performance with 3mg/kg (P=0.004, 72.7 ± 4.6 min) and 6mg/kg (P=0.001, 
71.6 ± 4.7 min) compared to the placebo (74.1 ± 5.4 min).  The 6mg/kg dose also resulted 
in a trend (using Bonferroni correction) to a significantly (P=0.04) improved performance 
compared to the 3mg/kg dose.  Results suggest that both 3 mg/kg and 6 mg/kg doses 
improve 40K time trial performance, but a dose-response effect may exist such that a 6 






CHAPTER 1: INTRODUCTION 
 Research has definitively established caffeine as an ergogenic aid for endurance 
performance (6,7,8,13,21,23,43,45,46,49,57,58,70,74,82,86,99,104).  For example, a 
recent review of 21 studies that measured the effects of caffeine on endurance 
performance with a time trial component; reported the mean improvement in 
performance with caffeine was 3.2% ± 4.3% (40).   
  Research suggests the optimal effective dose for caffeine supplementation may 
be ~5-6 mg/kg (1,3,5,6,13,18,22,27,32,41,49,56,57,59,66,74,75,82, 95,100,105,107).  
However, a recent review indicated that doses between 3 and 6 mg/kg have been 
commonly demonstrated to enhance performance (40).  Furthermore, a recent review by 
Burke (14) suggests a lack of a dose-response effect, in terms of further enhanced 
performance, with caffeine levels beyond ~3 mg/kg.   
  Prior studies have reported a dose-response effect for greater performance 
with a higher dose, albeit with dosage amounts less than ~ 3 mg/kg.  Using an exercise 
protocol similar to ours, Kovacs et al (70), reported significant improvement (p<0.01) in 
a cycling time trial with caffeine doses of ~2.1 mg/kg, ~3.2 mg/kg, and ~4.5 mg/kg 
compared to a placebo.  There was no difference in performance between the ~3.2 mg/kg 
and ~4.5 mg/kg doses, however they both resulted in a significantly (p<0.01) better 
performance than the ~2.1mg/kg dose.  Similarly, Jenkins et al (61) compared 15 minutes 
of maximal effort cycling performance using 1 mg/kg, 2 mg/kg, or 3 mg/kg doses.  The 2 
mg/kg dose statistically (p=0.02) improved performance compared to the placebo, the 3 
mg/kg dose trended (p=0.077) to improved performance compared to the placebo and the 





there were no differences (p>0.05) in performance between the 2 mg/kg or 3 mg/kg trial.  
Likewise, Cadarette et al. (15) reported a significant (p<0.05) improvement in time to 
fatigue on a treadmill run at ~80% VO2max with a 4.4 mg/kg dose ,but not a 2.2 mg/kg 
dose, compared to a placebo.  Although the authors reported no statistical (p>0.05) 
difference between time to exhaustion following the 4.4 mg/kg dose and the 2.2 mg/kg 
dose, the 4.4 mg/kg dose did increase time to exhaustion by 5.6 minutes compared to the 
2.2 mg/kg dose.     
 Although limited in number, studies that have compared dosage amounts greater 
than ~3 mg/kg (13, 66, 70, 88, 46) do seem to indicate a lack of a dose-response effect.  
For example, Passman et al (86) reported a significant (p<0.05) improvement in cycling 
time to exhaustion at 80% Wmax with caffeine doses of 5,9, and 13 mg/kg compared to a 
placebo, with no difference between treatments.  Likewise, Kovacs et al (70), reported 
significant improvement (p<0.01) in a cycling time trial with caffeine doses of ~3.2 and 
~4.5 mg/kg compared to a placebo, with no differences between treatments.  Finally, 
Bruce et al (13) reported a significant (p<0.05) improvement in a 2000 ergometer rowing 
time trial following ingestion of both 6 mg/kg and 9 mg/kg doses of caffeine compared to 
a placebo, with no difference between treatments.  
  Not only do the above studies suggest a lack of a dose-response effect, two 
studies (15,46) may indicate potential for negative effects with dosage amounts greater 
than 6mg/kg.  Graham and Spriet (46) did not report any statistical difference in a 
treadmill run time to exhaustion at 85% VO2max following ingestion of 3 mg/kg, 6 
mg/gk or 9 mg/kg doses.  Yet only the 3 and 6 mg/kg doses resulted in a statistically 





Cadarette et al (15) reported no statistical difference between a 4.4 mg/kg or 8.8 mg/kg 
dose on treadmill run time to fatigue at 80% VO2max yet only the 4.4 mg/kg dose 
resulted in a statistically significant (p<0.05) increase in performance compared to the 
placebo.   
 Thus it appears that if a dose-response effect exists; there may be a threshold 
effect such that the optimal dosage is most likely between 3-6 mg/kg. 
 Logically, a lack of a dose-response effect with caffeine may allow athletes to 
ingest lower doses of caffeine and avoid common side effects of caffeine use such as 
dizziness, headaches, anxiety, and tremors (58,110); thereby improving performance.  
These side-effects have been reported in studies using doses greater than or equal to 9 
mg/kg (46, 86)  In fact, Graham (42) notes that a caffeine dosage of approximately 5 
mg/kg causes saturation of the hepatic CYP1A2 system, which is the primary enzyme 
involved in caffeine metabolism and accounts for approximately 95% of caffeine 
clearance (51,52,67,89).  Thus larger doses (>6mg/kg) may produce increases in plasma 
caffeine levels and concomitantly increase negative side-effects (42).  Additionally, 
studies (13,86) have also reported that dosage amounts greater than 6 mg/kg resulted in 
individual subject urinary caffeine levels above the allowable doping limit (>12μg/ml) set 
by the International Olympic Committee whereas dosage amounts ≤ 6 mg/kg have not 
(13, 22,86).   
 The purpose of this present study was to compare the effect of caffeine doses of 3 
mg/kg and 6 mg/kg in trained cyclists on 40 kilometer cycling performance 
 Our hypothesis was that there would be no difference in 40k time trial 




CHAPTER 2: LITERATURE REVIEW 
Caffeine and endurance performance: 
 Research regarding the ergogenic effect of caffeine on endurance performance 
(Table 3.1) strongly supports the potential for caffeine to improve performance (8,46). 
However, according to Ganio et al (40), performance improvements in non-cycling 
endurance activities with a time-trial component may be somewhat less (in terms of 
percent improvement) compared to endurance cycling.  O’Rourke et al (82), Bridge et al 
(12), Bruce et al (13), and Anderson et al (1) all reported statistically significant 
performance improvements (5k run, 8k run, 2000 meter row, and 2000 meter row, 
respectively) less than 1.4% following caffeine supplementation which lends support to 
the findings of Ganio et al (40).  One study did report a 31% improvement in 
performance following caffeine supplementation, but that study was a run to exhaustion 
rather than a time trial (40).  Nevertheless, even a 1% improvement in performance can 
impact the outcome of time trial race.  For example, O’Rourke et al (82) reported that a 
1% performance improvement in well-trained runners equated to an 11 second 
improvement over the course of a 5 kilometer race.  Likewise, Bridge et al (12) reported 
that a 1.2% improvement in trained runners equated to a 23.8 second improvement over 
the course of an 8 kilometer race.  Thus caffeine appears to be an effective ergogenic aid 










Table 3.1 Effects of caffeine on endurance performance 
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Table 3.1(Concluded) Effects of caffeine on endurance performance 
Publication Subjects Caffeine Dose Protocol Improved 
Performance 
Key Results 
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Note: VO2max=maximal oxygen consumption; VO2peak=maximal oxygen consumption for that specific 





Caffeine and cycling performance: 
 The ergogenic effect of caffeine supplementation on cycling performance is well 
documented in the literature (Table 3.2).  Additionally, Ganio et al (40) performed a 
review of 21 studies that measured the effects of caffeine on endurance performance with 
a time trial component.  The 21 studies amounted to a total of 33 actual exercise trials 
broken into the following: 21 cycling, 6 running, 4 rowing, 1 swimming, and 1 cross-
country skiing.  The authors reported the mean improvement in performance following 
caffeine supplementation was greatest in the cycling trials (4.4 ± 5.0%) compared to 
running (0.9 ± 0.7%), rowing (1.1 ± 0.3%), swimming (1.7%) and cross-country skiing 
(1.1%); therefore suggesting caffeine potentially has a greater effect on cycling than any 
other endurance sport.  Research indicates the ergogenic effects of caffeine on cycling 
performance predominately equate to increased work performed during a time trial 
(16,24,57,61,70,75,107) or increased time to exhaustion 
(5,6,27,49,55,85,99,100,104,105).  However, the effect of caffeine supplementation on 
power production during cycling is somewhat more equivocal 
(1,32,50,66,70,95,107,111).  Although only three (50,107,109) of the aforementioned 
studies reported no statistically significant (p>0.05) effect on power production as a result 
of caffeine supplementation; two of them (50,107) reported performance improvements 
in peak power and mean power that could be considered practically significant.  For 
example, Walker et al (107) reported a trend to significance (p=0.09) for an increase in 
mean power over the course of a 30:00 time trial with caffeine (282 ± 39W) compared to 
the placebo (271 ± 42W).  The argument could also be made that the increase in mean 
power observed was a factor in the statistically improved (p=0.046) time trial 





(50) did not report a statistical increase (p>0.05) in peak power or mean peak power 
following a 30 second Wingate test.  Caffeine did increase peak power (1098 ± 198W, 
1049± 192 W) and mean peak power (802 ± 124W, 762± 104W) compared to the 
placebo.   
Table 3.2 Examining the effects of caffeine on cycling performance 







































































6mg/kg caffeine 1 
hour pre-exercise 
















55:00 prior to test, 
then 3 ml/kg at 20 
































































































Also, Trial D 
(58.9 ± 1.0 
min, 308 ± 9 
W) and Trial 
E (58.9± 1.2 





trial A (62.5 ± 
1.3 min, 292 ± 
10 W) trial B 
(61.5 ± 1.1 
min, 295 ± 9 
W), and trial 
C (60.4 ± 1.0 







Table 3.2 (Continued) Examining the effects of caffeine on cycling performance 
Publication Subjects Caffeine Dose Protocol Improved 
Performance 
Key Results 
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance 
Publication Subjects Caffeine Dose Protocol Improved 
Performance 
Key Results 
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance 
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance 
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance 
Publication Subjects Caffeine Dose Protocol Improved 
Performance 
Key Results 
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Table 3.2 (Concluded) Examining the effects of caffeine on cycling performance 
Publication Subjects Caffeine Dose Protocol Improved 
Performance 
Key Results 
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Mechanisms for improved performance: 
 Research regarding the mechanisms (Table 3.3) for improved performance 
observed following caffeine supplementation has established the following possible 
mechanisms: 1. Caffeine causes an increase in free fatty acid (FFA) oxidation and thus 
results in glycogen sparing. 2. Caffeine acts as an adenosine receptor antagonist in the 
central nervous system. 3. Caffeine affects neuromuscular function by increasing 
intracellular Ca
++ 
concentration via its effect on the sarcoplasmic recticulum 
(16,32,35,40,45,50,54,65,80,92,106).   
 Early studies thought the mechanism for improved endurance performance 
observed with caffeine supplementation to be a result of increased FFA oxidation and 
glycogen sparing (21,36,58).  However, FFA concentration may not provide conclusive 
evidence of FFA flow and oxidation during exercise (44).  For example, Tamopolsky et 
al (103), Van soren et al (105), Sungpil et al (100), and Bruce et al (13) all reported 
significantly elevated FFA concentrations following caffeine supplementation yet only 
Sungpil et al (100) reported a concomitant decrease in respiratory exchange ratio (RER).  
In addition, only one other study from Table 3.3 reported a significantly decreased RER 
following caffeine supplementation (108) Considering numerous studies in Table 3.3 
observed a significant performance effect following caffeine supplementation yet 
observed no difference in RER, rate of CHO or fat oxidation, or muscle glycogen net 
utilization it seems likely other mechanisms are primarily responsible for the ergogenic 
benefits of caffeine (13,49,61,92,105,107).  Furthermore improved performance has also 
been observed in protocols that would not generally elicit glycogen depletion 





 One such mechanism may be caffeine’s effect on the central nervous system via 
its role as an adenosine receptor antagonist (29,37,38,42,68,84,85,87,96).  Adenosine 
receptors are found in several isoforms (A1, A2, A26, and A3) throughout the nervous 
system as well as the vascular endothelium, heart, liver, adipose tissue, and muscle 
(30,38,91).  Adenosine has several inhibitory effects in both the central and peripheral 
nervous systems including limiting spontaneous and neurotransmitter-evoked firing of 
cortical neurons (33,72, 87).  Additionally, during moderate or high intensity exercise, 
adenosine concentration increases and binds to adenosine receptors located on the 
sensory nerve endings.  The resulting action may be an increase in pain signaling 
(77,81,94).  
 The antagonistic effects of caffeine are thought to extend to all the isoforms 
except the A3 isoform (37,96).  Because caffeine is able to cross the blood-brain barrier, a 
large effect of caffeine is found through its antagonism of the adenosine receptors in the 
brain and central nervous system (9,24,64).  Thus caffeine has the ability to decrease pain 
perception, and increase neuro-excitability, neurotransmitter release, and arousal 
(24,63,77,78,81,94). This effect serves to reduce the perceptual response in subjects to 
exercise thus allowing them to either exercise at a higher intensity or exercise longer at a 
fixed work rate (31, 98).  A recent meta-analysis of 21 studies found that rating of 
perceived exertion (RPE) during exercise was decreased by 5.6% with caffeine compared 
to a placebo (31).  Several studies from Table 3.3 also reported a reduction in RPE 
following caffeine supplementation (5,6,22,27,32,57).  Perhaps more indicative of the 
inhibitory effects of caffeine on adenosine receptors are the studies in which absolute 





performed was significantly greater following caffeine use (13,56,61,74,95,108).  This 
suggests the subjects in those studies may have had a reduced pain sensation or have been 
able to recruit more motor units (31). 
 The effects of caffeine’s antagonism of adenosine receptors are also thought to 
extend to an increase in neuro-excitability and motor neuron firing rates (50, 90)  
Additionally, caffeine has also been purported to act on neuromuscular function by 
facilitating an increase in calcium mobilization in the sacroplasmic recticulum 
(11,25,39,69,73,76,101).  An increase in neuro-excitability would seem to potentially 
increase maximal voluntary contraction, peak twitch torque, and motor unit firing rates; 
however three studies from Table 3.3 did not report an effect of caffeine on those 
variables. (76, 102, 103).  On the other hand, both Kalmar et al (65) and Del Coso et al 
(26) reported a positive effect on maximal voluntary contraction (MVC) as well as 
voluntary activation of motor units following caffeine supplementation.  Interestingly, 
Kalmar et al (65) did not find an increase in twitch amplitude during MVC despite a 
significant increase in MVC following caffeine use.  Thus leading the authors to 
speculate the increase in neuro-excitability takes place supraspinally (65).    
 Research has demonstrated the ability of caffeine to directly potentiate calcium 
release from the ryanodine receptor at the sacroplasmic recticulum in vitro (88).  Both 
Meyers et al (76) and Kalmar et al (65) reported a significant (p<0.05) increase in a 50% 
MVC held to exhaustion following caffeine supplementation leading the authors to 
speculate that caffeine had a ergogenic effect on calcium reuptake and availability in 
skeletal muscle.  Similarly, Tarnopolsky et al (102) reported a significant (p<0.05) 





force of contraction at 40Hz.  The authors attributed their difference in findings to 
research suggesting that low frequency electrical stimulation results in fatigue at the level 
of calcium release from the sacroplasmic reticulum whereas high frequency electrical 
stimulation fatigue occurs at the neuromuscular level (10,34);  thereby suggesting a direct 
effect of caffeine on skeletal muscle (102).  Although these findings support a potential 
ergogenic effect of caffeine at the level of the sarcoplasmic recticulum; research has also 
demonstrated that the plasma caffeine levels required to elicit calcium release from the 
sacroplasmic recticulum may be toxic to humans (38, 65).  Thus it is unclear the exact 
nature of caffeine’s effect on the sacroplasmic recticlum in humans. 
Table 3.3 Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
Publication Subjects Caffeine Dose Protocol Mechanism 
Observed 
Key Results 






































































































5 mg/kg + 

































mg/kg, or 3 
mg/kg + 450 






3 grams coffee 
(150-200 mg 
caffeine) + 
















































1100 meter run 




























No for both 
90:00 bout of 
















































not have an 





(p>0.05) or on 
FFA 
concentration 





RER for either 


















Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
Publication Subjects Caffeine Dose Protocol Mechanism 
Observed 
Key Results 
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
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Table 3.3(Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
Publication Subjects Caffeine Dose Protocol Mechanism 
Observed 
Key Results 
Kalmar et al 
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Table 3.3 (Continued Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
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Table 3.3(Concluded) Examining the purported mechanisms for ergogenic benefits observed with caffeine 
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or 
only reported metabolic data*) 
Publication Subjects Caffeine Dose Protocol Mechanism 
Observed 
Key Results 
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at 63 ± 5% 
VO2max in a 
hot chamber 
set at 36 ± 3 º 














































in all trials. 
Note: VO2max=maximal oxygen consumption; VO2peak=maximal oxygen consumption for that specific 
mode of exercise; FFA=free fatty acid; RER=respiratory exchange ratio; CHO=carbohydrate; CNS=central 
nervous system; RPE=rating of perceived exertion; EMG=electromyographic  
 
Differences in individual response to caffeine: 
 An interesting finding in studies that have reported individual results is that some 
individuals fail to positively respond to caffeine (Table 3.4).  Approximately 42% of all 
subjects (including all trials/protocols) from those studies either displayed a negative 
effect or no statistical change in performance with caffeine supplementation.  Yet all the 
studies except three (3,28,50), reported a significant performance effect with caffeine 
(p<0.05).  In addition, although Astorio et al (3) did not report a significant effect as a 





repetition maximum bench press and leg press as based on pre-established criteria. 
Likewise, although Desbrow et al (28) failed to find a difference (p>0.05) in a 7 kJ/kg 
cycling time trial performance between 1.5 mg/kg or 3 mg/kg caffeine doses compared to 
a placebo; 5 of the 9 subjects improved performance following ingestion of the 3 mg/kg 
dose compared to a placebo and 4 of 9 subjects improved performance following 
ingestion of the 1.5 mg/kg dose compared to a placebo.   Finally, Greer et al (50) did not 
find a statistical effect (p>0.05) on either peak power or mean peak power during a 30 
second Wingate test following caffeine supplementation; yet 12 of 18 subjects increased 
their peak power and 11 of 18 subjects increased their mean peak power following 
caffeine supplementation.  The potential for differences in individual response patterns to 
caffeine supplementation also does not appear to be mode or intensity specific; based on 
the varying protocols of studies included in Table 3.4.   One theory for differences in 
individual response to caffeine supplementation is habitual caffeine use.  The rationale 
behind this theory is due to research associating caffeine tolerance with an increase in 
adenosine receptor activity and a diminished β-adrenergic activity (20, 47, 71).  However, 
Doherty and Smith (31), in a recent meta-analysis concluded that period of subject 
withdrawl from caffeine did not appear to have any major influence on the effects of 
caffeine on RPE. Additionally, a study by Van Soren et al(105) from Table 3.2, did report 
an increase in time to exhaustion (+ 6 minutes) with  6 mg/kg of caffeine following 2 or 4 
days of  withdrawl compared to 0 days withdrawl, but there was no statistical difference 
between treatments and all 3 were significantly (p<0.05) better than the placebo.  
Likewise, Wiles et al (108) reported improved performance following caffeine 





cause, if any, for the difference in individual responses to caffeine has yet to be 
determined.   
 A recent study from our laboratory attempted to address a potential genetic link 
involving a polymorphism of the Cytochrome P450 1A2 (CYP1A2) gene (110). 
Approximately 95% of caffeine is metabolized in the liver by CYP1A2 (52, 67, 89).  
Research has shown that wide inter-individual differences in caffeine metabolism can 
occur as a result of variations in CYP1A2 activity (53, 67, 79).  More specifically, an A 
(adenine nucleotide)→C (cytosine nucleotide) substitution at position 734 in the 
CYP1A2 gene creates the F allele (53,93). The resulting CYP1A2 polymorphism 
presents itself as either an A allele or an F allele (53,93).  Carriers of the F allele (C 
variant) have a slow caffeine metabolism and link between caffeine intake and non-fatal 
myocardial infarction whereas carriers of the A allele (A variant) have a fast caffeine 
metabolism (19, 53, 93). In our prior study, we were able to group subjects according to 
whether or not they were carries of the C variant.  All subjects (11=A variant, 13=C 
variant) in the study underwent both a short duration cycling test to fatigue and a 40 
kilometer cycling time trial following 6mg/kg of caffeine ingestion one hour prior to 
exercise.  Although no significant effect (p=0.09) on short duration time to exhaustion 
was observed following caffeine supplementation, a strong trend (p=0.06) was observed 
for greater improvement in time to exhaustion for the A variant group (114.5 ± 37.9 
seconds) compared to the C variant group (96.6 ± 25.4 seconds).  Individually, 7 of 11 
subjects in the A variant group were considered responders to caffeine and 5 of 13 
subjects in the C variant group were considered responders to caffeine based on a criteria 





(p<0.05) reduction in 40k time trial time for the A variant group whereas it had no effect 
(p>0.05) on the C variant group.  Individually, 7 of 11 subjects in the A variant group 
were considered responders to caffeine (based on 5% reduction in time to completion) as 
compared to 2 of 13 subjects from the C variant group.  Additionally, none of the subjects 
in the A variant group had a slower 40k time following caffeine supplementation yet 4 
subjects in the C variant group did.  Likewise, 10 of 11 subjects in the A variant group 
improved their 40k time by at least 1:00 following caffeine supplementation while only 5 
of 13 subjects in the C variant group did the same.  In light of the fact the A variant group 
significantly improved their 40k time while the C variant did not, in addition to the A 
variant group displaying a stronger trend for improved time to exhaustion in the short 
duration trial compared to the C variant group; the results from this study lend support to 
a plausible connection regarding the effects of caffeine supplementation and the CYP1A2 
polymorphism (110) 
Table 3.4 Individual data for responders/non-responders to caffeine 
















































































Peak Power: 12 
responders and 6 
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Table 3.4 (Continued) Individual data for responders/non-responders to caffeine 
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workload=150%VO2peak. 
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Table 3.4 (Continued) Individual data for responders/non-responders to caffeine 
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Table 3.4 (Continued) Individual data for responders/non-responders to caffeine 
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Table 3.4 (Concluded) Individual data for responders/non-responders to caffeine 




















































































































Bench press: 12 
responders and 10 
non-responders 
(based on criteria 
of lifting at least 3 
kg more with 
caffeine)  
Leg Press: 11 
responders and 11 
non-responders 
(based on criteria 
of lifting at least 10 





















(116.4 ± 23.6 
kg) vs. placebo 
(114.9 ± 22.8 
kg) (p>0.05) 






caffeine had no 
statistical effect 
on maximal leg 
press (410.6 ± 
92.4 kg) vs. 
placebo (394.8 
± 95.4 kg) 
(p>0.05) yet 11 






For more information on Cytochrome P450 gene see text; VO2max=maximal oxygen consumption; 
VO2peak=maximal oxygen consumption for that specific mode of exercise; MVC=maximal voluntary 
contractions 
 
Influence of dosage amount, timing of ingestion, and training status on 
performance: 
 Research suggests the optimal effective dose for caffeine supplementation may be 
~5-6 mg/kg (1,3,5,6,13,18,22,27,32,41,49,56,57,59,66,74,75,82,95,100,105,107). 
Additionally, a review of 21 studies by Ganio et al (40) led the authors to suggest that 
dosage amounts between 3 and 6 mg/kg are commonly demonstrated to enhance 
endurance performance.   However, few studies have compared the ergogenic effects of 





  Studies that have reported a dose-response effect, generally found the effect with 
dosage amounts less than ~ 3 mg/kg.  For example, Kovacs et al (70), reported significant 
improvement (p<0.01) in a cycling time trial with caffeine doses of ~2.1 mg/kg, ~3.2 
mg/kg, and ~4.5 mg/kg compared to a placebo.  There was no difference in performance 
between the ~3.2 mg/kg and ~4.5 mg/kg doses, however they both resulted in a 
significantly (p<0.01) better performance than the ~2.1mg/kg dose.  Similarly, Jenkins et 
al (61) compared 15:00 of maximal effort cycling performance using 1 mg/kg, 2 mg/kg, 
or 3 mg/kg doses.  The 2 mg/kg dose statistically (p=0.02) improved performance 
compared to the placebo, the 3 mg/kg dose trended (p=0.077) to improved performance 
compared to the placebo and the 1 mg/kg dose did not improve (p>0.05) performance 
compared to the placebo.   However there were no differences (p>0.05) in performance 
between the 2 mg/kg or 3 mg/kg trial.  Likewise, Cadarette et al. (15) reported a 
significant (p<0.05) improvement in time to fatigue on a treadmill run at ~80% VO2max 
with a 4.4 mg/kg dose ,but not a 2.2 mg/kg dose, compared to a placebo.  Although the 
authors reported no statistical (p>0.05) difference between time to exhaustion following 
the 4.4 mg/kg dose and the 2.2 mg/kg dose, the 4.4 mg/kg did increase time to exhaustion 
by 5.6 minutes compared to the 2.2 mg/kg dose.  Finally, although Desbrow et al (28) 
failed to find a difference (p>0.05) in a 7 kJ/kg cycling time trial performance between 
1.5 mg/kg or 3 mg/kg caffeine doses compared to a placebo; 5 of the 9 subjects 
performed better following ingestion of the 3 mg/kg dose while only 2 subjects each 
performed better with the 1.5 mg/kg dose or placebo respectively.   
 In a recent review Burke (14) notes that there does not appear to be a dose-





mg/kg.  In support of this, Kang et al (66) reported a significant improvement (p<0.05) in 
a 30 second Wingate test with both a 2.5 mg/kg and 5.0 mg/kg caffeine dose compared to 
a placebo, but reported no difference between treatments.  Likewise, Passman et al (86) 
reported a significant (p<0.05) improvement in cycling time to exhaustion at 80% Wmax 
with caffeine doses of 5, 9, and 13 mg/kg with no difference between treatments.  Finally, 
Bruce et al (13) reported a significant (p<0.05) improvement in a 2000 ergometer rowing 
time trial following ingestion of both 6 mg/kg and 9 mg/kg doses of caffeine compared to 
a placebo, with no difference between treatments.  These studies, as well as studies by 
Kovacs et al (70), and Graham and Spriet (46) seem to suggest a lack of a dose-response 
relationship beyond ~3mg/kg of caffeine. 
 However, the study by Graham and Spriet (46) compared 3, 6, and 9 mg/kg doses 
to a placebo on treadmill run time to exhaustion at ~85% VO2max and reported a 
significant (p<0.05) improvement with both the 3 and 6 mg/kg doses compared the 
placebo.  Although no significant differences were found between the caffeine 
treatments, the 9 mg/kg dose did not result in a statistically significant (p>0.05) 
improvement compared to the placebo.  Likewise, Cadarette et al (15) reported no 
statistical difference between a 4.4 mg/kg or 8.8 mg/kg dose on treadmill run time to 
fatigue at 80% VO2max yet only the 4.4 mg/kg dose resulted in a statistically significant 
(p<0.05) increase in performance compared to the placebo.  Therefore potentially 
suggesting a negative effect may occur with dosage amounts greater than ~6mg/kg. 
 Thus it appears a dose-response effect may occur with dosage amounts less than 





amounts greater than ~3mg/kg. Likewise dosage amount greater than 6 mg/kg may also 
result in a reduced performance. 
 Peak plasma caffeine concentration is thought to occur 30-60 minutes following 
oral ingestion of caffeine (18,22).  This logically suggests maximal performance effects 
should occur ~1 hour following caffeine ingestion (11, 38, 42).  In fact, a majority of the 
studies reviewed in tables 3.1 and 3.2 used 1 hour pre-exercise as their benchmark for 
caffeine ingestion.  However only 3 of the studies (Table 3.5) actually compared multiple 
timing protocols with regards to ingestion of caffeine (6,18,22).  Bell et al (6) reported a 
significant (p≤ 0.05) improvement in time to exhaustion at 80% VO2 peak following 
caffeine ingestion 1, 3 and 6 hours prior to exercise with no significant differences 
between protocols among all subjects.  However when subjects were classified as users 
(n=13, ≥300 mg caffeine/day) and non-users (n=8, <50mg caffeine/day), only the non-
users demonstrated a significant performance improvement following caffeine ingestion 
6 hours prior to exercise.  Conway et al (18) reported a non-significant (p=0.08) 
improvement in time trial performance  with both caffeine ingestion of either 6 mg/kg 1 
hour pre-exercise or 3 mg/kg 1 hour pre-exercise and 3 mg/kg 45:00 into exercise. 
Although not significant (p>0.05), the single dose of caffeine resulted in a 48 second 
(23.4 min vs. 24.2 min) improvement in time trial performance.  Cox et al (22) reported a 
significant improvement(p=0.04) in time trial performance (3.4%) following 120 minutes 
of steady state(SS) cycling at 70% VO2peak with caffeine ingestion of 6 mg/kg 1 hour 
pre-exercise; whereas caffeine ingested in either 6 x 1 mg/kg doses every 20:00 





ingested in the final 20 minutes of SS and during the time trial resulted in a non-
significant (p=0.06) trend toward improvement (3.1%).   
 Finally, the ergogenic effects of caffeine may be influenced by the training status 
of the subjects used (7).  For example, Collomp et al (17) reported a significant (p<0.01) 
improvement in 100 meter swim time in trained subjects, but not in untrained subjects, 
following caffeine supplementation. However, Kang et al (66) did not find a difference in 
performance on a 30 second Wingate test between professional cyclists and PE students 
following caffeine supplementation.  Likewise, O’Rourke et al (82) did not find a 
difference in 5 kilometer running time between well trained runners and recreational 
runners (mostly team sport-athletes) following caffeine supplementation.  The lack of 
studies comparing the response of trained vs. untrained subjects does not allow for a 
feasible conclusion; however it is certainly area that could use more research. 
Table 3.5 Influence of dosage amount, timing of ingestion, and training status on performance 
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance 
Publication Subjects Caffeine Dose Protocol Influence 
Observed 
Key Results 
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance 
Publication Subjects Caffeine Dose Protocol Influence 
Observed 
Key Results 
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance 
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance 
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance 
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Table 3.5 (Concluded) Influence of dosage amount, timing of ingestion, and training status on performance 
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Notes:W=Watts;VO2max=maximal oxygen consumption;VO2peak=maximal oxygen consumption for that 
specific mode of exercise;Wmax=maximal power output 
 
Summary: 
 In conclusion, caffeine is a proven ergogenic aid for endurance performance and 
research also indicates it may provide ergogenic benefits for short-term, high intensity 
exercise as well.  A majority of studies suggest the optimal time for ingestion of caffeine 
is 1 hour pre-exercise, likely due to the fact peak plasma caffeine levels occur ~30:00-
60:00 minutes after ingestion.  Additionally, the optimal dosage amount appears to be in 
the range of ~3 to ~6mg/kg although doses above and below those amounts have 
demonstrated ergogenic effects.  While the exact mechanism(s) through which caffeine 
exerts its ergogenic effects are unclear, research suggests caffeine’s actions on the central 
nervous system and/or sarcoplasmic recticulum may be a leading cause.  However there 
are still relatively few studies exploring the ergogenic benefits of caffeine in relation to  
issues such as training status, dose-response effect, caffeine habituation, and actual field 





individual response to caffeine that may in part be due a CYP1A2 Polymorphism. 
Therefore, while the ergogenicity of caffeine has been well established, future research 
should examine physiological mechanisms and other factors (training status, genotype, 

































CHAPTER 3: METHODOLOGY 
Subjects:  16 male, recreationally competitive cyclists were recruited for this study (age 
=26.4 ± 7.4 yrs, height = 176.6 ± 6.8 cm, weight = 71.8 ± 7.8 kg, VO2max =64.7 ± 9.1 
ml/kg/min).  Subjects were healthy, free from known disease, and free from medications.  
Informed consent was obtained from all subjects prior to participation per the James 
Madison University Institutional Review Board. 
 
Maximal Exercise Test: Subjects performed an exercise test to exhaustion to determine 
maximal oxygen consumption.  The test began at a work rate of 150 W on an indoor 
cycle trainer (Racermate Veletron: Seattle, WA), with load increases of 20 W each 
minute until volitional exhaustion.  The highest 1-minute oxygen uptake value obtained 
during the test was defined as peak oxygen uptake (VO2peak).  The highest power output 
obtained during the test was defined as peak power output (POpeak).  Oxygen uptake was 
monitored continuously via a Sensormedics Vmax (Yorba Linda, CA) metabolic 
measurement system calibrated in advance of all tests.  Heart rate was monitored using a 
Polar Heart Rate Monitor (Lake Success, NY). 
 
40 Kilometer Time Trials: All subjects were tested on 4 separate occasions separated by 
a minimum of 5 full days and a maximum of 10 days.  The first trial served as a 
familiarization trial and the remaining trials as treatments.  All testing occurred in the 
morning following a 10 hour fast and 24 hour abstinence from caffeine ingestion.  One 
hour prior to testing, subjects ingested either a placebo, 3mg/kg caffeine, or 6 mg/kg 
caffeine capsule administered in double-blind fashion along with 22 ounces of a 6% 
carbohydarate/electrolyte solution.  The order of testing for different dosages was 





Velotron: Seattle, WA) on a computer-simulated course.  The course consisted of eight 
laps of a flat, five-kilometer loop.  Subjects were allowed to observe distance completed 
on the course via a video display, but were blinded from any performance indicators, 
including power output, lap time and total time.  In addition, no data from the trials was 
provided until subjects completed the entire study.  Oxygen uptake (VO2), respiratory 
exchange ratio (RER), heart rate (HR), and Ratings of Perceived Exertion (RPE), using 
the original Borg scale, were obtained at 10km intervals throughout the trial. 
 
 Statistical Analyses: Potential differences in 40K time, average power output (Watts), 
HR, RPE, VO2, and RER were assessed using repeated measures ANOVA with treatment 
as a within-subjects factor.  A priori level of significance was set at p<0.05.  Any 
significant differences were analyzed using a dependent t-test with a Bonferroni 
correction with the a-priori level of significance set at p<0.017.   All data are reported as 














CHAPTER 4: RESULTS 
40 Kilometer Time Trials: 
 Figure 1 displays average 40 kilometer time trial performance following each 
treatment.  Caffeine significantly (P<0.017) improved performance in the 3mg/kg (72.7 ± 
4.6 min) and 6mg/kg (71.6 ± 4.7 min) trials compared to placebo (74.1 ± 5.4 min).  There 
was also a trend (P=0.04, Bonferroni correction) for enhanced performance for 6mg/kg as 
compared to 3mg/kg 
Average Power output, HR, RPE, VO2, and RER: 
 Table 1 displays average power output, HR, RPE, VO2 and RER for each of the 
40k time trials.  Average power data was able to be collected on only 12 subjects.  Due to 
technical difficulties, complete data for VO2 and RER was collected for only 9 subjects.  
Average power output was significantly greater with 3mg/kg and 6 mg/kg compared to 
placebo (P<0.017).  The 6 mg/kg dose also resulted in a significantly (P=0.012) greater 
average power output compared to the 3 mg/kg dose.   Average HR was significantly 
greater with 3mg/kg and 6mg/kg compared to placebo (P<0.017).  The 6 mg/kg dose also 
resulted in a trend (P=0.09) for a significantly greater average HR than the 3 mg/kgdose. 













Table 1: Average values for Power output, Heart Rate, Rating of Perceived Exertion, VO2, and Respiratory 




Power output (Watts) 
 
191.4 ± 18.4* 202.2 ± 24.4*# 183.9 ± 18.9 
HR 
 
162.9 ± 11.9* 165.6 ± 12.9* 156.8 ± 14.1 
RPE 
 
15.1 ± 1.5 15.2 ± 1.5 15.1 ± 1.5 
VO2 (L/min) 
 
3.48 ± 0.6 
(~76%VO2max) 
3.66 ± 0.6 
(~80%VO2max) 
3.47 ± 0.7 
(~75%VO2max) 
RER 0.89 ± 0.03 0.88 ± 0.04 0.89 ± 0.03 
* Significantly (P<0.017) different than placebo 
















































CHAPTER 5: DISCUSSION 
 Although doses of both 3 mg/kg and 6 mg/kg significantly improved 40 kilometer 
time trial performance compared to a placebo, there was a trend (p=0.04, Bonferroni 
correction) for a larger performance improvement with the 6 mg/kg dose.  The 
ergongenic effect of caffeine on performance found with both the 3 mg/kg and 6 mg/kg 
doses is in agreement with previous research (2, 6,12,27,43,57, 74,75, 82,100, 105,107).   
 Our findings of a trend suggesting a dose-response relationship exists between 
low and high doses of caffeine, such that the high dose further enhances performance, are 
in contrast with previous research.   In a recent review Burke (14) notes that there does 
not appear to be a dose-response effect to caffeine beyond a dose of ~3 mg/kg.  In 
support of Burke’s hypothesis, Kang et al (66) reported a significant improvement 
(p<0.05) in a 30 second Wingate test with both a 2.5 mg/kg and 5.0 mg/kg caffeine dose 
compared to a placebo, but reported no difference between treatments.  Likewise, 
Passman et al (86) reported a significant (p<0.05) improvement in cycling time to 
exhaustion at 80% Wmax with caffeine doses of 5, 9, and 13 mg/kg with no difference 
between treatments.  Finally, Bruce et al (13) reported a significant (p<0.05) 
improvement in a 2000 ergometer rowing time trial following ingestion of both 6 mg/kg 
and 9 mg/kg doses of caffeine compared to a placebo, with no difference between 
treatments.  These studies, as well as studies by Kovacs et al (70), and Graham and Spriet 
(46) do seem to suggest a lack of a dose-response relationship beyond ~3mg/kg of 
caffeine. 
 Interestingly, Graham and Spriet (46) compared 3, 6, and 9 mg/kg doses to a 





(p<0.05) improvement with both the 3 and 6 mg/kg doses compared the placebo.  
However, although the 9 mg/kg dose did not result in a statistically significant (p>0.05) 
difference in performance compared to either the 3 mg/kg or 6 mg/kg dose, it did not 
improve performance (p>0.05) compared to the placebo.  Likewise, Cadarette et al (15) 
reported no statistical difference between a 4.4 mg/kg or 8.8 mg/kg dose on treadmill 
time to fatigue at 80% VO2max: yet only the 4.4 mg/kg dose resulted in a statistically 
significant (p<0.05) increase in performance compared to the placebo.  Therefore, it is 
possible that a negative dose-response occurs with dosage amounts greater than ~6mg/kg.  
The results of our study, as well as the two aforementioned studies may indicate that ~5- 
6 mg/kg is indeed the optimal dose needed for improved performance.  However, the 
theory is only speculative at this point because we didn’t include a dose greater than 6 
mg/kg to allow for comparison.  Also, neither Anderson et al (1), Bruce et al (13), nor 
Passman et al (86) reported a negative effect on performance with doses ≥ 9 mg/kg as 
compared to doses ≤ 6 mg/kg.   
 Other prior research has reported a dose-response effect for improved 
performance with increased dosages, but generally with dosage amounts less than ~ 3 
mg/kg.  Using an exercise protocol similar to ours, Kovacs et al (70), reported significant 
improvement (p<0.01) in a cycling time trial with caffeine doses of ~2.1 mg/kg, ~3.2 
mg/kg, and ~4.5 mg/kg compared to a placebo.  There was no difference in performance 
between the ~3.2 mg/kg and ~4.5 mg/kg doses, however they both resulted in a 
significantly (p<0.01) better performance than the ~2.1mg/kg dose.  Similarly, Jenkins et 
al (61) compared 15:00 of maximal effort cycling performance using 1 mg/kg, 2 mg/kg, 





compared to the placebo, the 3 mg/kg dose trended (p=0.077) to improved performance 
compared to the placebo and the 1 mg/kg dose did not improve (p>0.05) performance 
compared to the placebo.   However there were no differences (p>0.05) in performance 
between the 2 mg/kg or 3 mg/kg trial.  Likewise, Cadarette et al. (15) reported a 
significant (p<0.05) improvement in time to fatigue on a treadmill run at ~80% VO2max 
with a 4.4 mg/kg dose ,but not a 2.2 mg/kg dose, compared to a placebo.  Although the 
authors reported no statistical (p>0.05) difference between time to exhaustion following 
the 4.4 mg/kg dose and the 2.2 mg/kg dose, the 4.4 mg/kg did increase time to exhaustion 
by 5.6 minutes compared to the 2.2 mg/kg dose.  Finally, although Desbrow et al (28) 
failed to find a difference (p>0.05) in a 7 kJ/kg cycling time trial performance between 
1.5 mg/kg or 3 mg/kg caffeine doses compared to a placebo; 5 of the 9 subjects 
performed better following ingestion of the 3 mg/kg dose while only 2 subjects each 
performed better with the 1.5 mg/kg dose or placebo respectively.  Thus it appears 
research suggests a dose-response effect may occur with dosage amounts less than ~3 
mg/kg and perhaps with dosage amounts greater than ~ 6mg/kg; such that dosages above 
or below those amounts may not improve performance to the degree dosage amounts 
within ~3-~6 mg/kg improve performance.   
 To our knowledge only one other study (46) has directly compared caffeine 
dosages within the range suggested (40,42) to be “optimal” (3 mg/kg-6mg/kg) needed for  
ergogenic effects.  The results of the study by Graham and Spriet, as described in the 
previous paragraph, do not indicate a dose-response effect for greater performance with 6 
mg/kg as compared to 3 mg/kg (46). Yet, differences in both study protocol (time to 





exercise mode (running vs. cycling) make it difficult to directly compare studies.  For 
example, time to exhaustion protocols may result in a large degree of intra and inter-
subject variability (40).  In fact, Jeukendrup et al (62) reported a coefficient of variation 
of 26.6% following 5 repeated trials of a time to exhaustion protocol whereas a time trial 
protocol only resulted in a coefficient of variation of 3.4% over the course of 5 repeated 
trials.  Thus leading the authors to suggest that time trial protocols are not influenced by a 
potential learning or order effect.  Similarly, Palmer et al (83) reported a 1% coefficient 
of variation for a laboratory 40k cycling trial.  One other study (66) did use a dosage 
protocol very similar (2.5 mg/kg, 5mg/kg, placebo) to ours.  Again, the authors reported a 
statistical improvement with caffeine (p<0.05) compared to placebo but did not find a 
difference in performance between the two doses.  The protocol used (30 second Wingate 
Test) is vastly different from ours in terms of both duration and energy systems used 
which again makes a direct comparison difficult.  Finally, one other study used a similar 
exercise mode and protocol to the present study as well as compared at least two dosage 
amounts greater than ~ 3mg/kg (70).  The authors failed to find a dose effect between 
doses of ~3.2 mg/kg and ~4.5 mg/kg.  However the subjects in that trial ingested the 
caffeine in combination with a carbohydrate-electrolyte solution before, 1/3, and 2/3 of 
the way through the time trial, thus making a direct comparison difficult.   
Mechanisms: 
 A primary mechanism for improved performance observed with caffeine is 
thought to be its effect on adenosine receptors.  Adenosine receptors are known to limit 
spontaneous and neurotransmitter-evoked firing of cortical neurons (33,72, 87) as well as 





is an adenosine receptor antagonist (29,37,38,68,84,85,87,96), it has the ability to 
decrease pain perception, and increase neuro-excitability, neurotransmitter release and 
arousal (24, 63, 77, 78, 81, 94).  This effect serves to reduce the perceptual response 
(rating of perceived of exertion or RPE) in subjects to exercise, thus allowing them to 
either exercise at a higher intensity or exercise longer at a fixed work rate (31 ,98). In 
fact, a recent meta-analysis of 21 studies found that RPE during exercise was decreased 
by 5.6% with caffeine compared to a placebo (31).  Additionally, several studies have 
reported the same absolute RPE at the end of exercise following both caffeine and 
placebo trials yet the work performed was significantly greater following caffeine use 
(13, 56, 61, 74, 95, 108).  This suggests the subjects in those studies may have had a 
reduced pain sensation or were able to recruit more motor units (31).  Our study found no 
differences in RPE (p>0.05) among treatments despite the fact that both caffeine trials 
were significantly (p<0.017) faster than the placebo and the 6 mg/kg dose resulted in a 
trend (p=0.04, Bonferroni correction) to a faster time than the 3 mg/kg dose.  The lack of 
difference in RPE also occurred despite a significant (p<0.017) increase in avearage 
power output (n=12) and heart rate with both caffeine trials compared to the placebo trial.  
Thus, it seems subjects may have experienced a reduction in pain sensation, or were able 
to recruit more motor units at the same perceived level of work following caffeine 
ingestion. It is plausible the higher dose of caffeine had a greater antagonistic effect on 
adenosine receptors than the lower dose which could explain the observed trend towards 
improved performance with the higher dose of caffeine, especially in light of the fact that 





compared to the 3 mg/kg dose.  However, data from the 3 dose-response studies that did 
record subject RPE do not support this contention (13,15,61).     
 A recent study from our laboratory indicated a possible link between a CYP1A2 
polymorphism (A/C) and the ergogenic effects of caffeine on performance (110).  The 
authors were able to classify 11 of 24 subjects as carriers of the A variant and the other 
13 subjects as carriers of the C variant.  A distinct difference in performance following 
caffeine supplementation was observed between groups such that A variant homozygotes 
displayed significant (p<0.05) improvement in a 40K time trial while carriers of the C 
variant displayed no effect (p>0.05) (110).  Therefore it is plausible the CYP1A2 
polymorphism may influence individual response to caffeine supplementation and hence 
influence whether or not a dose-response relationship is present.  The current study 
included 4 known C variants from the previous study (110).  Using the same statistical 
analysis as with the entire group, the data for the known C variant subjects was markedly 
different from the data for the whole group.  For example, although no significant 
difference in 40K time was found between the 3 mg/kg dose and 6 mg/kg dose,  a trend 
occurred towards faster time with the 3 mg/kg dose as compared placebo (p= 0.05, 
Bonferroni correction) while no trend was found between the 6 mg/kg dose and placebo 
(p =0.14).  In addition, although the mean 40K time was fastest among the entire group 
following supplementation with the 6 mg/kg dose, the mean 40K time among the 4 
known C variants was fastest following supplementation with the 3 mg/kg dose.  Finally, 
the 4 known C variants were removed from data analysis and the results (n=12) indicated 
a stronger trend (p=0.03), toward greater improvement in time trial performance with the 





group).  Additionally, without the known C variants, the 6 mg/kg dose resulted in a 
significantly improved time trial performance (p=0.01) compared to the placebo whereas 
the 3 mg/kg dose only resulted in a trend towards improvement compared to the placebo.  
These differences found with the C variants are novel and may have contributed to our 
findings of a trend (p=0.04) towards a dose-response effect between 3 mg/kg and 6 
mg/kg whereby we may have had a disproportionate amount of non-C variants (A 
variants homozygotes) as subjects.  On the other hand, it is also possible we had 
additional unknown C variants among our subjects.  Therefore because C variants have 
been shown to respond poorly to 6 mg/kg of caffeine in this current study as well as in 
our previous study (110); the potential for a significant improvement in performance with 
the 6 mg/kg dose compared to the 3 mg/kg dose may have been masked.   However, we 
do not know the genotype of the remaining 12 subjects; therefore we can only theorize as 
to the extent, if any, of a relationship between dose-response effect and genotype.  
Limitations:  
 As previously described, the primary mechanism for improved performance 
observed with caffeine is thought to be its effect on adenosine receptors.   Because 
caffeine functions as an adenosine receptor antagonist throughout the central nervous 
system (29,37,38,42,68,84,85,87,96) and because caffeine tolerance (as a result of 
habitual caffeine use) has been shown result in an increase in adenosine receptor activity 
and a decrease in β-adrenergic activity (20,47,71); prior/habitual caffeine use has been 
cited as a potential reason for differences in response to caffeine.  Specifically, low 
caffeine users may be more sensitive to low doses of caffeine whereas habitual caffeine 





research is equivocal regarding caffeine habituation.  Van Soren et al (105) measured 
cycling time to exhaustion following ingestion of 6 mg/kg caffeine after 0, 2 and 4 days 
withdrawl from caffeine use as compared to the placebo.  An improvement in greater 
time to exhaustion (+ 6 minutes) was observed after 2 and 4 days withdrawl as compared 
to 0 days withdrawl, however all 3 trials were significantly (p<0.05) better than the 
placebo and none of the 3 trials significantly differed from each other.  Likewise Bell et 
al (6) divided 21 subjects into users (≥ 300 mg/day n=13) and non-users (< 50 mg/day) of 
caffeine.  Caffeine significantly (p≤ 0.05) improved cycling time to exhaustion compared 
to a placebo following ingestion of 5 mg/kg caffeine taken 1, 3, or 6 hours prior to 
exercise.  However only the non-users demonstrated significant (p≤ 0.05) improvement 
compared to the placebo following caffeine ingestion 6 hours prior to exercise.  
Conversely, Wiles et al (108) reported a statistical (p<0.05) improvement in 1500 meter 
run time following ingestion of 150-200 mg of caffeine compared to a placebo, but found 
no association between habitual caffeine use and performance improvement.  Likewise, 
Tarnopolsky et al (102) reported a statistical (p<0.05) improvement in force of 
contraction at 20Hz during a 2:00 tetanic stimulation of the peroneal nerve following 
ingestion of 6 mg/kg caffeine compared to a placebo with no difference between caffeine 
users (> 500 mg/day, n=6) and non-users (<50 mg/day, n=6).  Finally, in a recent meta-
analysis, Doherty and Smith (31) concluded that a period of subject withdrawl from 
caffeine did not appear to have any major influence on the effects of caffeine on Rating 
of Perceived Exertion (RPE).   
 Data from our study appeared to indicate a preferential response to the 6 mg/kg 





7 of them performed better following ingestion of the 6 mg/kg dose as compared to the 3 
mg/kg dose.  Only 1 of the other dose-response studies analyzed their results in terms of 
dose response and caffeine habituation, and they also did not find any apparent 
relationship between optimal dose and habitual caffeine use (46).  In that study, Graham 
and Spriet (46) used both 3mg/kg and 6 mg/kg doses of caffeine and failed to find a 
difference between either dose on treadmill time to exhaustion.  Although our studies 
differed in terms of mode of exercise, we did compare the same dosage amounts.  
Therefore, previous research suggests our findings regarding a dose-response effect do 
not appear to be influenced by our subject’s previous caffeine use. 
 Another potential limitation may have been the previous training of the subjects in 
the week leading up to each time trial.  Our data collection took place late summer and 
early fall which is a popular time for cycling races and triathlons; therefore some subjects 
were training for upcoming races while participating in our study.  While we did not 
regulate subject training in the days leading up to each trial, we did ask subjects to 
maintain their normal training schedule.  Although no quantitative data was obtained, 
several subjects noted they used the time trials as their hard training ride for the week or 
performed other modes of exercise (i.e. swimming/running) the day prior to their time 
trial.  In some prior studies subjects were instructed to refrain from strenuous or 
exhaustive training for 24 (61) or 48 (70) hours prior to exercise.  However, Desbrow et 
al (28) used dosage amounts similar to the previous two studies, but did not find a dose-
response effect for improved performance despite asking their subjects to refrain from 
heavy training for 24 hours prior to each trial.  Likewise, Graham and Spriet (46) used 





normal training schedule yet they failed to find a dose-response effect indicating 
enhanced performance with a higher dose.  While it is plausible that prior exercise by our 
subjects may have influenced the outcome of their trials and hence the dose-response 
effect; previous studies suggest otherwise.  Additionally, any effect of prior exercise on 
the performance of our subjects would have resulted in an increase in error variance in 
our study which would have made it harder to find the resultant trend for improved 
performance with 6mg/kg as compared to 3mg/kg of caffeine.  Nevertheless, future dose-
response studies would be well-served to keep training logs on each subject.   
Application: 
 Data from our study provides evidence that ergogenic effects from caffeine can be 
elicited by both 3 mg/kg and 6 mg/kg of caffeine in trained cyclists performing a 40K 
time trial.  Our data also suggests that 6 mg/kg of caffeine may contribute to an improved 
performance as compared to the 3 mg/kg dose.  This finding is in contrast to what 
previous literature suggests regarding a lack of dose-response improvement in 
performance for dosage amounts greater than ~3mg/kg.  However the results of some 
studies may indicate a threshold effect with caffeine such that rate of performance 
improvement decreases beyond ~6mg/kg.  Thereby suggesting the optimal dosage 
amount is between ~3mg/kg and ~6mg/kg.   Studies comparing doses between ~3mg/kg 
and 6mg/kg (or greater) are very limited, thus future studies should compare multiple 
doses at amounts 3mg/kg and larger.   
 The mechanisms contributing to the trend toward a greater performance following 
ingestion of 6 mg/kg of caffeine as compared to 3 mg/kg are unknown.  However 





especially as it relates to the CYP1A2 Polymorphism.  Therefore future studies should 
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